Vireo Growth Inc.

Vireo Growth Inc. is a U.S.-based cannabis company that cultivates, manufactures, distributes, and sells cannabis products through wholesale channels and owned or operated dispensaries. Its operations are concentrated in state-licensed markets across Maryland, Minnesota, Missouri, Nevada, New York, and Utah.

5,6 %

47,3 %

−25,3 %

+170,4 %

1.59

1.28

— Vireo Growth Inc.
%
Cultivation25% Growing cannabis plants and producing raw material for downstream processing and sale.
Manufacturing20% Processing cultivated cannabis into finished products for wholesale and retail channels.
Wholesale25% Selling cannabis products to third-party dispensaries and other licensed buyers.
Retail Dispensaries30% Operating Green Goods and other dispensaries that sell directly to approved patients and adult-use customers.

Vireo sells to two main customer groups: licensed third-party dispensaries in wholesale markets and end consumers who...

  • Medical patientsprimary

    Buy cannabis products through dispensaries for approved medical use and consistent product access.

  • Adult-use consumersprimary

    Purchase cannabis products at retail stores in states where adult-use sales are permitted.

  • Wholesale dispensariessecondary

    Buy cannabis products for resale in licensed third-party retail outlets.

Vireo operates in six U.S. states: Maryland, Minnesota, Missouri, Nevada, New York, and Utah...

  • •Operations span Maryland, Minnesota, Missouri, Nevada, New York, and Utah
  • •Retail sales come from 36 dispensaries across the six-state footprint
  • •Wholesale sales are concentrated in Maryland, Minnesota, and New York
  • •State licensing shapes where the company can cultivate, process, and sell
  • •Limited-license markets can support local supply discipline and access

Vireo’s stated focus is on building a customer-centric cannabis platform across cultivation, manufacturing, wholesale,...

01
Deepen vertical integrationmedium-term

Owning cultivation, manufacturing, wholesale, and retail improves control over supply and customer access.

02
Strengthen presence in limited-license marketsmedium-term

Restricted licensing can support durable local market positions and distribution access.

03
Increase customer-centric retail executionshort-term

Direct retail relationships can improve brand visibility and capture more end-market demand.

Vireo faces regulatory and licensing risk because cannabis operations depend on state approvals, local compliance, and...

high

Regulatory approval risk for transactions and asset sales

Cannabis assets often require government and regulatory consent before closing.

Scope
Asset Sale / RSA-related transactions
Materiality
high
high

Transaction completion risk

The company may not obtain approvals or satisfy conditions precedent, preventing expected benefits.

Scope
Acquisition / restructuring-related activity
Materiality
high
medium

Multi-state operating complexity

Different state rules, retail footprints, and wholesale channels increase operational complexity.

Scope
Maryland, Minnesota, Missouri, Nevada, New York, Utah
Materiality
medium
medium

Cannabis market competition and pricing pressure

Wholesale and retail cannabis markets can be fragmented and price competitive.

Scope
Wholesale and dispensary sales
Materiality
medium
Revenue recognition by channel
Affects quarterly comparability and reported revenue timing
Inventory valuation and adjustments
Can change cost of sales and margin presentation
Stock-based compensation
Affects operating expenses and adjusted earnings reconciliation
Debt extinguishment and interest expense
Can materially affect other expense and net income
Warrant fair value accounting
Introduces earnings volatility unrelated to core cannabis operations

Verano Holdings Corp.

VRNO · Agricultural Production-Crops

MARIMED INC.

MRMD · Medicinal Chemicals & Botanical Products

Trulieve Cannabis Corp.

TRLV · Medicinal Chemicals & Botanical Products

Jushi Holdings Inc.

JUSH · Medicinal Chemicals & Botanical Products

Green Thumb Industries Inc.

GTBIF · Agricultural Production-Crops

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

: 29/04/2026